Published Date : Sep 25, 2019
The VITAL test, which includes Omega-3 trail and vitamin D is the most recent and largest test for figuring out the effect of fish oil and vitamin D on cancer patients. The trail is known to have some positive impacts on battling with cardiovascular diseases and tumors. Till date, the results have been mixed, but promising with respect to certain outcomes. This was confirmed by the updated meta analyses. The recent results are expected to be presented between September 25 to September 28, 2019, in The North American Menopause Society (NAMS) Annual Meeting, Chicago.
Fish Oil and Vitamin D Both Had Little But Effective Outcomes in Cardiovascular Events
Around 26,000 people from the U.S., both women and men were included in the global VITAL trail. After over five years of treatments and studies, the outcome seems to be positive with certain trials. For instances, even though, Omega-3 fatty acids or fish oil represented just a little and non-significant decrease in basic cardiovascular events, these were related to the substantial decrease in heart attacks and strokes. The most effective treatment advantage of VITAL was witnessed in the individuals who consume fish under the cohort median of 1.5 serving in a week. However, it is not the same with the consumption rate over the mentioned level. Moreover, African-Americans were likely to witness the highest risk reduction. The advantages on heart health are fortified now by latest Omega-3 meta-analyses at randomized trials.
Dr. JoAnn Manson, from Brigham and Women's Hospital, affiliated by Harvard Medical School conducted the study. He is also the co-author of it. As per the study, even Vitamin D supplements also hardly had any reduction in cardiovascular events. However, it was related to the statistical decrease in the overall cancer mortality for the individuals who were under trials for around two years. This effect is also fortified through a vitamin D meta-analyses trials.